Ziprasidona en la psicosis dopaminérgica parkinsoniana

Durán-Ferreras, Eduardo; Álvarez-López, María R.; García-Moreno, J M; Chacón, José

doi:10.33588/rn.4608.2007378

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Olanzapine is an effective choice but it can cause more adverse effects on motor function than quetiapine [1]. Aripiprazole and ziprasidone were also suggested as effective and relatively safe treatment options in PD associated psychosis [13,14]. Clozapine should be used cautiously in view of the risk of agranulocytosis and there is a mandatory requirement for blood monitoring [15].…”

Section: Discussionmentioning

confidence: 99%

Electroconvulsive Therapy as an Effective Alternative in Parkinson’s Disease Associated Psychosis: A Case Report and Brief Review of the Literature

Sarıkaya¹

2014

J Med Cases

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Electroconvulsive Therapy as an Effective Alternative in Parkinson’s Disease Associated Psychosis: A Case Report and Brief Review of the Literature

Sarıkaya¹

2014

J Med Cases

View full text Add to dashboard Cite

show abstract

Diagnosis and management of psychosis in Parkinson's disease

Latoo¹,

Mistry²,

Dunne³

2012

Prog Neurol Psychiatry

View full text Add to dashboard Cite

show abstract

A Systematic Review and Case Series of Ziprasidone for Psychosis in Parkinson’s Disease

Younce

Davis

Black

2019

JPD

View full text Add to dashboard Cite

The atypical antipsychotic ziprasidone has been considered inappropriate for use in patients with Parkinson’s disease (PD), as most atypical antipsychotics worsen parkinsonism. However, the current evidence for safety and efficacy of ziprasidone in PDP has not been evaluated in a systematic fashion. We review published experience with ziprasidone for treating psychosis in PD via systematic search of MEDLINE, Embase, Cochrane CENTRAL, and Clinicaltrials.gov with terms related to “ziprasidone” and “Parkinson’s disease”, inclusive of case reports and prospective studies. We also add seven cases of ziprasidone exposure in patients in our center with idiopathic PD or Lewy body dementia (DLB), selected by retrospective query of all clinical data since 1996. In our review, two prospective trials and 11 case reports or series were found, with ziprasidone found to be generally effective for treatment of psychosis and with few adverse events reported. Our case series did not support efficacy of ziprasidone; it was generally safe in PD, but two patients with DLB had adverse motor events. We conclude that, although ziprasidone occasionally can produce substantial worsening of motor signs, it usually is well tolerated, and may provide in some cases a useful alternative to quetiapine, clozapine and pimavanserin, particularly in the acute care setting. Further randomized controlled studies are needed.

show abstract

Ziprasidona en la psicosis dopaminérgica parkinsoniana

Cited by 3 publications

References 0 publications

Electroconvulsive Therapy as an Effective Alternative in Parkinson’s Disease Associated Psychosis: A Case Report and Brief Review of the Literature

Electroconvulsive Therapy as an Effective Alternative in Parkinson’s Disease Associated Psychosis: A Case Report and Brief Review of the Literature

Diagnosis and management of psychosis in Parkinson's disease

A Systematic Review and Case Series of Ziprasidone for Psychosis in Parkinson’s Disease

Contact Info

Product

Resources

About